Summit Therapeutics SMMT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$1.21B-401% | -$1.08B-388% | -$921.62M-369% | -$746.08M-361% | -$240.76M-108% | ||
| $165K+89.7% | $146K+64.0% | $126K+29.9% | $104K-4.6% | $87K-35.6% | ||
| $794.12M+1,411% | $732.42M+1,337% | $631.66M+1,197% | $520.27M+1,631% | $52.57M+152% | ||
| —— | —— | —— | —— | —— | ||
| $23.54M+49.7% | $12.93M+8.8% | $9.68M— | $14.63M— | $15.72M— | ||
| -$5.26M-147% | -$4.87M-166% | $14.35M+252% | $13.48M+293% | $11.24M+302% | ||
| $24K— | $82K— | $107K— | $101K— | —— | ||
| -$384.05M-122% | -$322.93M-127% | -$269.67M-139% | -$206.88M-112% | -$173.14M-84.7% | ||
| $480K-13.8% | $657K+373% | $507K+299% | $494K+305% | $557K+605% | ||
| $662.28M+12.8% | $484.99M-28.7% | $149.49M-71.8% | $317.04M-33.4% | $587.05M+141% | ||
| —— | —— | —— | $618.32M+75.2% | $537.51M+67.4% | ||
| -$334.66M— | -$174.31M— | —— | —— | —— | ||
| $7.43M+56.3% | $5.65M+107% | $5.13M— | $5.32M— | $4.76M— | ||
| $613.65M+48.9% | $617.53M+52.5% | $43.71M-89.4% | $214.04M+3.3% | $412.03M+5,815% | ||
| —— | —— | $13K— | $105K— | —— | ||
| —— | —— | —— | $269.44M+542% | $150.23M+364% | ||
| $8.26M— | $7.01M— | —— | —— | —— | ||
| $165K+89.7% | $146K+64.0% | $126K+29.9% | $104K-4.6% | $87K-35.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$1.64M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $24K— | $82K— | $107K— | $101K— | —— | ||
| $8M+132% | -$4.87M-166% | $4.67M+351% | $8.5M+398% | $3.45M+643% | ||
| $662.28M+12.8% | $484.99M-28.7% | $149.49M-71.8% | $317.04M-33.4% | $587.05M+141% | ||
| —— | —— | —— | $618.32M+75.2% | $537.51M+67.4% | ||
| $7.43M+74.0% | $5.65M+107% | $5.13M+124% | $4.72M+441% | $4.27M+460% | ||
| —— | —— | —— | $7.81M+499% | $6.26M— | ||
| $1.04M— | $291K— | $164K— | $72K— | —— | ||
| -$384.53M-121% | -$323.59M-127% | -$270.17M-139% | -$207.38M-112% | -$173.7M-85.1% | ||
| -$384.53M-121% | -$323.59M-127% | -$270.17M-139% | -$207.38M-112% | -$173.7M-85.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Summit Therapeutics generate?
- Summit Therapeutics (SMMT) generated -$384.1M in operating cash flow over the trailing twelve months.
- What is Summit Therapeutics's free cash flow?
- After $480.0K of capital expenditures, Summit Therapeutics's free cash flow was -$384.5M over the trailing twelve months, down 121.4% year over year.
- Where does Summit Therapeutics's cash flow data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.